Business Segments · D&A
Business Segments — D&A
Pfizer Business Segments — D&A increased by 5.1% to $348.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.1%, from $331.00M to $348.00M.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2017
Last reportedQ1 2026
Rolls up toD&A
How to read this metric
High levels often correlate with significant past capital expenditures or large-scale acquisitions of drug portfolios.
Detailed definition
The systematic allocation of the cost of tangible and intangible assets over their useful lives within the Biopharma seg...
Peer comparison
Standard 'D&A' metric found in segment-level cash flow or operating expense disclosures.
Metric ID:
pfe_segment_biopharma_depreciation_and_amortizationHistorical Data
9 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $359.75M | $359.75M | $359.75M | $203.25M | $203.25M | $203.25M | $203.25M | $331.00M | $348.00M |
| QoQ Change | — | +0.0% | +0.0% | -43.5% | +0.0% | +0.0% | +0.0% | +62.9% | +5.1% |
| YoY Change | — | — | — | — | -43.5% | -43.5% | -43.5% | — | +5.1% |
Range$203.25M – $359.75M
CAGR-1.6%
Avg YoY Growth-31.3%
Median YoY Growth-43.5%
Current Streak5 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — d&a?
- Pfizer (PFE) reported business segments — d&a of $348.00M in Q1 2026.
- How has Pfizer's business segments — d&a changed year-over-year?
- Pfizer's business segments — d&a increased by 5.1% year-over-year, from $331.00M to $348.00M.
- What does business segments — d&a mean?
- The non-cash expense representing the wear and tear of physical assets and the expiration of intangible assets in the Biopharma segment.